Bioasis Announces Stock Option Grants
August 31 2018 - 8:46AM
Business Wire
BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF;
TSX.V:BTI), a biopharmaceutical company developing its xB3 TM
proprietary platform technology for the delivery of therapeutics
across the blood-brain barrier (BBB) and the treatment of CNS
disorders in areas of high unmet medical need, including brain
cancers and neurodegenerative diseases, today announced that it has
granted stock options to acquire a total of 1,020,000 common shares
at a price of $0.47 per share to directors of the company. These
options vest over a period of 12 months from the date of the grant,
expire five years from the date of the grant and are governed by
the terms of the company’s stock option plan.
On behalf of the Board of Directors of Bioasis Technologies
Inc.
Mark Day, Ph.D., Director and President & Chief Executive
Officer
ABOUT BIOASIS
Bioasis Technologies, Inc. is a biopharmaceutical company
developing the xB3 TM platform, a proprietary technology for the
delivery of therapeutics across the blood-brain barrier (BBB) and
the treatment of CNS disorders in areas of high unmet medical need,
including brain cancers and neurodegenerative diseases. The
delivery of therapeutics across the BBB represents the final
frontier in treating neurological disorders. The in-house
development programs at Bioasis are designed to develop symptomatic
and disease-modifying treatments for brain-related diseases and
disorders. The company maintains headquarters in Richmond, Canada
with offices in Guilford, Conn., United States. Bioasis trades on
the TSX Venture Exchange under the symbol “BTI” and on the OTCQB
under the symbol “BIOAF.” For more information about the company,
please visit www.bioasis.us.
“Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.”
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180831005199/en/
Media & Investor Relations:Bioasis Technologies,
Inc.Catherine London, 917-763-2709Catherine@bioasis.us
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Apr 2023 to Apr 2024